Genetic variants and risk of cervical cancer: Epidemiological evidence, meta-analysis and research review

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 121, Issue 6, 2014, Pages 664-673

  Zhang, X ^a   Zhang, L ^a   Tian, C ^b   Yang, L ^c   Wang, Z ^a  

^a SHANDONG UNIVERSITY   (China)

^b Suzhou Municipal Center for Disease Control and Prevention   (China)

^c Hangzhou Center for Disease Control and Prevention   (China)

Author keywords

Epidemiological evidence; genetic variants; meta analysis; uterine cervical neoplasms

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; XRCC3 PROTEIN; CTLA4 PROTEIN, HUMAN; DNA BINDING PROTEIN; HLA DQ ANTIGEN; HLA-DQA1 ANTIGEN; HLA-DQB1 ANTIGEN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

ARTICLE; CANCER RISK; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DATA BASE; EPIDEMIOLOGICAL DATA; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; EPIDEMIOLOGICAL EVIDENCE; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIANTS; GENETICS; REVIEW; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX TUMOR;

EPIDEMIOLOGICAL EVIDENCE; GENETIC VARIANTS; META-ANALYSIS; UTERINE CERVICAL NEOPLASMS;

CTLA-4 ANTIGEN; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HLA-DQ ALPHA-CHAINS; HLA-DQ BETA-CHAINS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84899430712     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12638     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Munger K,. The role of human papillomaviruses in human cancers. Front Biosci 2002; 7: d641-9.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
4. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-71.
5. Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2009; 100: 1191-7.
6. Zhang X, Dai B, Zhang B, Wang Z,. Vitamin A and risk of cervical cancer: a meta-analysis. Gynecol Oncol 2012; 124: 366-73.
7. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93.
8. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012; 47: 517-21.
9. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE,. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
10. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40: 827-34.
11. Zhang B, Beeghly-Fadiel A, Long J, Zheng W,. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011; 12: 477-88.
12. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008; 37: 120-32.
13. Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, Dolan SM, et al. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol 2009; 170: 269-79.
14. Sagoo GS, Little J, Higgins JP,. Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med 2009; 6: e28.
15. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-9. W264.
16. Ioannidis JP, Ntzani EE, Trikalinos TA,. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004; 36: 1312-8.
17. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61.
18. Wells GA, Shea B, O'Connel Dl, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [ http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp ].
19. Wigginton JE, Cutler DJ, Abecasis G,. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 887-93.
20. Lau J, Ioannidis JP, Schmid CH,. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.
21. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
22. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
23. Harbord RM, Egger M, Sterne JA,. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006; 25: 3443-57.
24. Perales G, Burguete-Garcia AI, Dimas J, Bahena-Roman M, Bermudez-Morales VH, Moreno J, et al. A polymorphism in the AT-hook motif of the transcriptional regulator AKNA is a risk factor for cervical cancer. Biomarkers 2010; 15: 470-4.
25. Shekari M, Sobti RC, Tamandani DM, Malekzadeh K, Kaur P, Suri V,. Association of genetic polymorphism of the DNA base excision repair gene (APE-1 Asp/148 Glu) and HPV type (16/18) with the risk of cervix cancer in north Indian population. Cancer Biomark 2008; 4: 63-71.
26. Chatterjee K, Williamson AL, Hoffman M, Dandara C,. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer. J Med Virol 2011; 83: 630-6.
27. Xiong XD, Qiu FE, Fang JH, Shen Y, Liang C, Jiang W, et al. Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. Mutat Res 2009; 662: 10-5.
28. Kang S, Kim JW, Park NH, Song YS, Park SY, Kang SB, et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer 2007; 17: 492-6.
29. Kruszyna L, Lianeri M, Roszak A, Jagodzinski PP,. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clin Biochem 2010; 43: 545-8.
30. Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007; 121: 2451-7.
31. Meissner Rde V, Barbosa RN, Fernandes JV, Galvao TM, Galvao AF, Oliveira GH,. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev 2007; 31: 371-4.
32. Cayan F, Ayaz L, Aras-Ates N, Dilekci E, Dilek S, Tamer-Gumus L,. N-acetyltransferase 2 gene polymorphism in patients with cervical cancer. Int J Gynecol Cancer 2009; 19: 1186-9.
33. He X, Ye F, Zhang J, Cheng Q, Shen J, Chen H,. REV1 genetic variants associated with the risk of cervical carcinoma. Eur J Epidemiol 2008; 23: 403-9.
34. Singh H, Jain M, Mittal B,. Role of TGF-beta1 (-509C>T) promoter polymorphism in susceptibility to cervical cancer. Oncol Res 2009; 18: 41-5.
35. Kim YH, Kim MA, Park IA, Park WY, Kim JW, Kim SC, et al. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol 2010; 119: 232-6.
36. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG,. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-9.
37. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
38. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW,. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
39. Kawajiri K, Fujii-Kuriyama Y,. P450 and human cancer. Jpn J Cancer Res 1991; 82: 1325-35.
40. Autrup H,. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000; 464: 65-76.
41. Hayes JD, Pulford DJ,. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
42. Ketterer B,. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 1988; 202: 343-61.
43. Arend WP,. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-40.
44. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR,. Interleukin-10. Annu Rev Immunol 1993; 11: 165-90.
45. Chang CH, Furue M, Tamaki K,. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995; 25: 394-8.
46. Abdel-Rahman SZ, El-Zein RA,. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000; 159: 63-71.
47. Khanna KK, Jackson SP,. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 247-54.